MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention

Salama, Abou Bakr M.; Khalil, Wael A.; Al-Zaky, Manar; Abd-Allah, Somia H.; Kandil, Nader Talaat; Abdelsabour, Ahmed; Shaker, Ahmed Mohammed; Hasanein, Mesbah Taha; Luciani, Giovanni Battista; Azzazy, Hassan M.E.

doi:10.1007/s12265-020-10020-9

Cited by 9 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of cardiac muscle‐enriched miR‐208a tend to be higher 71 or significantly higher 72 in patients with CHD than in healthy volunteers, suggesting the possible use of miR‐208a as a diagnostic marker for CHD. Several studies, including a meta‐analysis comprising eight similar studies, have also supported the use of miR‐208a as a highly sensitive and specific biomarker for the diagnosis of acute MI, 73‐75 and a positive correlation was observed between circulating levels of miR‐208a and the severity of coronary atherosclerosis 74,76 . Notably, 24‐h plasma miR‐208a levels in patients with acute MI were found to decrease significantly after successful percutaneous coronary intervention (PCI), suggesting that miR‐208a could be used as an indicator of treatment response 74 .…”

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 89%

“…Notably, 24‐h plasma miR‐208a levels in patients with acute MI were found to decrease significantly after successful percutaneous coronary intervention (PCI), suggesting that miR‐208a could be used as an indicator of treatment response 74 . Increased circulating miR‐208a could also predict the occurrence of slow coronary flow 77 and no‐reflow in PCI 75 . With regard to prognosis, increased circulating miR‐208a is positively associated with poor outcomes after acute MI 75,78 .…”

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 99%

“…Increased circulating miR‐208a could also predict the occurrence of slow coronary flow 77 and no‐reflow in PCI 75 . With regard to prognosis, increased circulating miR‐208a is positively associated with poor outcomes after acute MI 75,78 . Briefly, the plasma levels of miR‐208a remain elevated for up to 90 days post‐MI, 79 and patients with higher miR‐208a expression levels have increased cardiac risk, such as a higher Killip class, CK‐MB peak, cTnT peak, and low‐density lipoprotein levels, as well as a lower 1‐year survival rate than those with lower miR‐208a expression levels 78 .…”

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 99%

See 2 more Smart Citations

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Xiang

Chen

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) and cancer, which are the leading causes of mortality globally, have been viewed as two distinct diseases. However, the fact that cancer and CVDs may coincide has been noted by cardiologists when taking care of patients with CVDs caused by cancer chemotherapy; this entity is designated cardio‐oncology. More recently, patients with CVDs have also been found to have increased risk of cancers, termed reverse cardio‐oncology. Although reverse cardio‐oncology has been highlighted as an important disease state in recent studies, how the diseased heart affects cancer and the potential mediators of the crosstalk between CVDs and cancer are largely unknown. Here, we focus on the roles of cardiac‐specific microRNA‐208a (miR‐208a) in cardiac and cancer biology and explore its essential roles in reverse cardio‐oncology. Accumulating evidence has shown that within the heart, increased miR‐208a promotes myocardial injury, arrhythmia, cardiac remodeling, and dysfunction and that secreted miR‐208a in the circulation may have novel roles in promoting tumor proliferation and invasion. This review, therefore, provides insights into the novel roles of miR‐208a in reverse cardio‐oncology and strategies to prevent secondary carcinogenesis in patients with early‐ or late‐stage heart failure.

show abstract

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 89%

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 99%

Section: The Physiology Of Mir‐208a and Its Impact On Cvdsmentioning

confidence: 99%

See 1 more Smart Citation

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Xiang

Chen

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…This characteristic could potentially make them useful as biomarkers for timely diagnosis, staging, and monitoring of disease during treatment. For instance, multiple studies have shown that miR-208a in exosomes released from injured cardiomyocytes after MI has the advantages of strong myocardial specificity, high sensitivity and strong stability, and is positively correlated with the indexes of myocardial function before and after therapy [112,[179][180][181]. The functional diversity of exosomes secreted by cardiac cells also suggests that these various cell types should be further explored as potential sources of therapeutic exosomes.…”

Section: Discussionmentioning

confidence: 99%

Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction

Liu

Wang

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Acute myocardial infarction has long been the leading cause of death in coronary heart disease, which is characterized by irreversible cardiomyocyte death and restricted blood supply. Conventional reperfusion therapy can further aggravate myocardial injury. Stem cell therapy, especially with mesenchymal stem cells (MSCs), has emerged as a promising approach to promote cardiac repair and improve cardiac function. MSCs may induce these effects by secreting exosomes containing therapeutically active RNA, proteins and lipids. Notably, normal cardiac function depends on intracardiac paracrine signaling via exosomes, and exosomes secreted by cardiac cells can partially reflect changes in the heart during disease, so analyzing these vesicles may provide valuable insights into the pathology of myocardial infarction as well as guide the development of new treatments. The present review examines how exosomes produced by MSCs and cardiac cells may influence injury after myocardial infarction and serve as therapies against such injury. Graphical Abstract

show abstract

“…The diagnosis performance of this microRNA is comparable to the known used cardiac biomarkers: CK-MB, cTnT and to hs-cTnT (p = 1.000). Authors believe that miRNA-208a is significantly better than routine biomarkers and is more specific and reliable than miR-30e [99]. miR-208b was considerably raised in the AMI subjects compared with healthy people, whereas miR-26a and miR-191 were decreased [100].…”

Section: Mirna-208mentioning

confidence: 98%

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Gosav

Ouatu

Bădescu

et al. 2021

Life

View full text Add to dashboard Cite

Regardless of the newly diagnostic and therapeutic advances, coronary artery disease (CAD) and more explicitly, ST-elevation myocardial infarction (STEMI), remains one of the leading causes of morbidity and mortality worldwide. Thus, early and prompt diagnosis of cardiac dysfunction is pivotal in STEMI patients for a better prognosis and outcome. In recent years, microRNAs (miRNAs) gained attention as potential biomarkers in myocardial infarction (MI) and acute coronary syndromes (ACS), as they have key roles in heart development, various cardiac processes, and act as indicators of cardiac damage. In this review, we describe the current available knowledge about cardiac miRNAs and their functions, and focus mainly on their potential use as novel circulating diagnostic and prognostic biomarkers in STEMI.

show abstract

MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention

Cited by 9 publications

References 32 publications

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Contact Info

Product

Resources

About